# A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer

> **NCT00251472** · PHASE2 · COMPLETED · sponsor: **Veeda Oncology** · enrollment: 72 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Paclitaxel Albumin Nanoparticle for Injectable Suspension

## Key facts

- **NCT ID:** NCT00251472
- **Lead sponsor:** Veeda Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2012-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251472, "A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00251472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*